Results 161 to 170 of about 49,161 (205)
Some of the next articles are maybe not open access.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Cefepime is a potent, broad‐spectrum, fourth‐generation cephalosporin with enhanced activity against most gram‐positive aerobic bacterial pathogens and many gram‐negative aerobic bacteria that are resistant to other cephalosporins. The drug's zwitterionic structure contributes to more rapid penetration of gram‐negative bacterial cell membranes, and its
T C, Hardin, T S, Jennings
openaire +2 more sources
Cefepime is a potent, broad‐spectrum, fourth‐generation cephalosporin with enhanced activity against most gram‐positive aerobic bacterial pathogens and many gram‐negative aerobic bacteria that are resistant to other cephalosporins. The drug's zwitterionic structure contributes to more rapid penetration of gram‐negative bacterial cell membranes, and its
T C, Hardin, T S, Jennings
openaire +2 more sources
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria [PDF]
Journal of Antimicrobial Chemotherapy, 2017 Background: Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' effect, potentiating β-lactams targeting PBP3.
David M Livermore, Neil Woodford
exaly +3 more sources